Opaleye Management, a 10% owner, buys $33,019 of Grace Therapeutics stock

Opaleye Management Inc., which holds a 10% stake in Grace Therapeutics, Inc. (NASDAQ:GRCE), recently made a series of purchases totaling approximately $33,019 of the company's common stock. These transactions occurred over a three-day period, from November 3 to November 5, 2026. The prices paid for the shares varied between $1.77 and $1.81 per share as the stock traded near its 52-week low of $1.67, marking a 48.6% decline year-to-date.

InvestingPro analysis suggests the stock may be undervalued, trading below its Fair Value, and Opaleye Management views GRCE as having more cash than debt on its balance sheet, with analysts projecting profitability for the year. On November 3, Opaleye Management acquired 10,328 shares at an average price of $1.7894, while on November 4, they bought an additional 5,027 shares at an average of $1.8023.

The final purchase on November 5 consisted of 3,087 shares at an average of $1.7746. The shares are owned indirectly by Opaleye, L.P., with Opaleye Management Inc. acting as the investment manager. Now beneficially owning 3,054,853 shares of Grace Therapeutics common stock, Opaleye Management disclaims ownership except for its financial stake. This report was AI-generated and reviewed by an editor.